192 related articles for article (PubMed ID: 24214521)
1. Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapy.
Madadi P; Amstutz U; Rieder M; Ito S; Fung V; Hwang S; Turgeon J; Michaud V; Koren G; Carleton BC;
J Popul Ther Clin Pharmacol; 2013; 20(3):e369-96. PubMed ID: 24214521
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update.
Crews KR; Gaedigk A; Dunnenberger HM; Leeder JS; Klein TE; Caudle KE; Haidar CE; Shen DD; Callaghan JT; Sadhasivam S; Prows CA; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2014 Apr; 95(4):376-82. PubMed ID: 24458010
[TBL] [Abstract][Full Text] [Related]
3. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype.
Crews KR; Gaedigk A; Dunnenberger HM; Klein TE; Shen DD; Callaghan JT; Kharasch ED; Skaar TC;
Clin Pharmacol Ther; 2012 Feb; 91(2):321-6. PubMed ID: 22205192
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics: why standard codeine doses can have serious toxicities or no therapeutic effect.
Kelly PA
Oncol Nurs Forum; 2013 Jul; 40(4):322-4. PubMed ID: 23803265
[No Abstract] [Full Text] [Related]
5. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
6. Suspected opioid overdose case resolved by CYP2D6 genotyping.
Shaw KD; Amstutz U; Jimenez-Mendez R; Ross CJ; Carleton BC
Ther Drug Monit; 2012 Apr; 34(2):121-3. PubMed ID: 22406651
[TBL] [Abstract][Full Text] [Related]
7. [Problem forte--is paracetamol-codeine combination rational?].
Helland A; Spigset O; Slørdal L
Tidsskr Nor Laegeforen; 2004 Aug; 124(16):2084-7. PubMed ID: 15334119
[TBL] [Abstract][Full Text] [Related]
8. Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure.
Badaoui S; Hopkins AM; Rodrigues AD; Miners JO; Sorich MJ; Rowland A
AAPS J; 2021 Jan; 23(1):15. PubMed ID: 33404848
[TBL] [Abstract][Full Text] [Related]
9. Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer.
Voronov P; Przybylo HJ; Jagannathan N
Paediatr Anaesth; 2007 Jul; 17(7):684-7. PubMed ID: 17564651
[TBL] [Abstract][Full Text] [Related]
10. Codeine and tramadol analgesic efficacy and respiratory effects are influenced by CYP2D6 genotype.
Stamer UM; Stüber F
Anaesthesia; 2007 Dec; 62(12):1294-5; author reply 1295-6. PubMed ID: 17991273
[No Abstract] [Full Text] [Related]
11. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
[TBL] [Abstract][Full Text] [Related]
12. Can extremely low or high morphine formation from codeine be predicted prior to therapy initiation?
Lötsch J; Rohrbacher M; Schmidt H; Doehring A; Brockmöller J; Geisslinger G
Pain; 2009 Jul; 144(1-2):119-24. PubMed ID: 19395173
[TBL] [Abstract][Full Text] [Related]
13. The Use of Codeine and Tramadol in the Pediatric Population-What is the Verdict Now?
Fortenberry M; Crowder J; So TY
J Pediatr Health Care; 2019 Jan; 33(1):117-123. PubMed ID: 30545525
[TBL] [Abstract][Full Text] [Related]
14. Codeine intoxication associated with ultrarapid CYP2D6 metabolism.
Gasche Y; Daali Y; Fathi M; Chiappe A; Cottini S; Dayer P; Desmeules J
N Engl J Med; 2004 Dec; 351(27):2827-31. PubMed ID: 15625333
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics for Safe Codeine Use in Sickle Cell Disease.
Gammal RS; Crews KR; Haidar CE; Hoffman JM; Baker DK; Barker PJ; Estepp JH; Pei D; Broeckel U; Wang W; Weiss MJ; Relling MV; Hankins J
Pediatrics; 2016 Jul; 138(1):. PubMed ID: 27335380
[TBL] [Abstract][Full Text] [Related]
16. The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.
Wu X; Yuan L; Zuo J; Lv J; Guo T
Eur J Clin Pharmacol; 2014 Jan; 70(1):57-63. PubMed ID: 24077935
[TBL] [Abstract][Full Text] [Related]
17. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation.
Eckhardt K; Li S; Ammon S; Schänzle G; Mikus G; Eichelbaum M
Pain; 1998 May; 76(1-2):27-33. PubMed ID: 9696456
[TBL] [Abstract][Full Text] [Related]
18. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).
Matic M; Nijenhuis M; Soree B; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GAPJM; Weide JV; Wilffert B; Swen JJ; Guchelaar HJ; Deneer VHM; van Schaik RHN
Eur J Hum Genet; 2022 Oct; 30(10):1105-1113. PubMed ID: 34267337
[TBL] [Abstract][Full Text] [Related]
19. Wither codeine?
Tremlett MR
Paediatr Anaesth; 2013 Aug; 23(8):677-83. PubMed ID: 23668390
[No Abstract] [Full Text] [Related]
20. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study.
Willmann S; Edginton AN; Coboeken K; Ahr G; Lippert J
Clin Pharmacol Ther; 2009 Dec; 86(6):634-43. PubMed ID: 19710640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]